| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| ln Vitro |
Angstrom6 has an IC50 of 10–100 nM, which effectively stops the migration of OVCAR8, OVCAR3, ES2, IGROV-1, MDA-MB-468, and MDA-MB361 cells [3]. As demonstrated by focal adhesion induction and MAP/ERK disrupting phosphorylation, Angstrom6 increases CD44-dependent interaction with hyaluronic acid and stimulates CD44-mediated signaling [3].
|
|---|---|
| ln Vivo |
Angstrom6 (100 mg/kg; subcutaneously twice daily) reduces the number of lung lesions produced by intravenous B16-F10 melanoma cells by 50% [3].
|
| Animal Protocol |
Animal/Disease Models: C57Bl/6 mice (carrying B16-F10 cells) [3]
Doses: 100 mg/kg Route of Administration: Sc; twice (two times) daily for 11 days Experimental Results: The number of pulmonary nodules was diminished, and the number of pulmonary metastases was diminished to control 50%. For prostate cancer model: human PC-3M-LN4 prostate cancer cells were injected orthotopically into the prostates of male BALB/c nu/nu mice. Angstrom6 was administered (dose and route not specified in this review) and lymph node metastases were measured. [2] For glioblastoma models: U87MG human glioma cells were implanted subcutaneously or intracranially in BALB/c nu/nu mice. Animals were divided into treatment groups receiving Angstrom6 alone, cisplatin alone, or combination. Tumor growth and survival were monitored. [2] For melanoma lung metastasis model: B16-F10 melanoma cells were injected into tail veins of C57BL/6 mice. Angstrom6 treatment was given, and lungs were evaluated for lesions at day 11. [2] For mammary tumor models: MDA-MB-231 human mammary carcinoma cells were implanted subcutaneously in BALB/c nu/nu mice, or Mat B-III syngeneic mammary carcinoma cells were inoculated in Fisher rats. Angstrom6 was administered alone or with tamoxifen. Tumor growth and metastasis were assessed. [2] For CLL xenograft model: ZAP-70-positive B-cell lymphocytes isolated from patients were injected into immunodeficient mice. Mice were treated with Angstrom6 or vehicle control, and CLL burden was evaluated. [2] For choroidal neovascularization models: Laser-induced CNV was performed in mice, rats, and primates. Angstrom6 was administered subcutaneously (mice, rats) or intravitreally (primates). New vessel formation was quantified. [2] For diabetic retinopathy model: Streptozotocin was used to induce diabetes in Brown Norway rats. Angstrom6 treatment was given, and retinal vascular permeability and VE-cadherin levels were measured. [2] |
| References |
|
| Molecular Formula |
C39H62N10O15
|
|---|---|
| Molecular Weight |
910.967589855194
|
| CAS # |
220334-14-5
|
| PubChem CID |
42638946
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
25
|
| Heavy Atom Count |
64
|
| Complexity |
1750
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
O=C([C@@H]1CCCN1C([C@H](CO)NC([C@H](CO)NC([C@@H]1CCCN1C([C@H](CCCCN)NC(C)=O)=O)=O)=O)=O)N1CCC[C@H]1C(N[C@H](C(N[C@H](C(=O)O)CCC(N)=O)=O)CCC(=O)O)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~109.77 mM)
H2O : ≥ 100 mg/mL (~109.77 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.74 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.74 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.74 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0977 mL | 5.4887 mL | 10.9773 mL | |
| 5 mM | 0.2195 mL | 1.0977 mL | 2.1955 mL | |
| 10 mM | 0.1098 mL | 0.5489 mL | 1.0977 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
